“…On the other hand, thromboprophylaxis itself could be risky for both fetus and mother; so one should be rational, meaning that one should estimate the risk and identify patients who really need thromboprophylaxis. Based on these estimates, in cases of thrombophilia with no prior VTE the American College of Chest Physicians (ACCP) recommends antepartal low-molecular weight heparin (LMWH) prophylaxis only for homozygous women with FVL or prothrombin gene mutations, who have a positive family history for VTE 26,43,44 . Based on these estimates, in cases of thrombophilia with no prior VTE the American College of Chest Physicians (ACCP) recommends antepartal low-molecular weight heparin (LMWH) prophylaxis only for homozygous women with FVL or prothrombin gene mutations, who have a positive family history for VTE 26,43,44 .…”